iShares Global Tech ETF vs Medpace Holdings Inc — how do they compare? iShares Global Tech ETF trades at $142.15, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). Which is the better fit depends on your goals.
| IXN | MEDP | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $149.74 | $620.59 |
52-Week Low | $94.42 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Signals from Pluang's Aura AI — not financial advice
IXN trades at $142.26, up 2.04% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows strong momentum near resistance at $142. Recent news highlights its global tech exposure, though some analysts express caution on valuations.
The outlook is mixed; technical strength supports near-term upside, but high expectations and concentration risk warrant caution. Investors should weigh growth potential against valuation concerns in the tech sector.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →